Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Sudarshan Chemical Industries - Shifting gears from normalisation to growth - ICICI Securities

Posted On: 2020-10-26 23:02:02


Sudarshan Chemical Industries' (SCIL) Q2FY21 EBITDA rose 2.1% YoY to Rs677mn on recovery in volumes. In Sep'20, the company achieved highest production volumes, which can make H2 much stronger, if sustained. SCIL is shifting gears from normalisation of production to accelerating growth. It plans to relaunch yellow pigment in Dec'20 and add one more product in HPP category in Mar'21 and Sep'21. SCIL continues to work towards becoming world's third-largest pigment company (revenues of >US$500mn) and has adopted three key strategies: 1) Improve distribution by better go-to-market plans, 2) enhance product portfolio with specialty pigments, and 3) attain cost leadership. We increase our target price to Rs533 (from Rs484) as we raise our FY22 P/E multiple to 22x (from 20x). Maintain ADD. Numbers updated for annual report.

- Demand strong; supply normalising. SCIL's pigment revenue grew 0.4% YoY (+17.8% QoQ) to Rs4bn despite two weeks shut down of Roha plant. This was due to recovery in India demand which has reached to pre-Covid levels (though SCIL cautious as part of demand could be channel inventory filling); and exports demand continues to remain strong. It has reached highest production volumes in Sep'20. It expects demand to remain strong in India due to festive season which tapers post Diwali. Growth was led by volumes; realisations have been stable. Overall, Sudarshan has exposure (in same pecking order) in coatings, plastics, print and cosmetics. However, domestic demand is more skewed towards plastics and print, while less in cosmetic as buyers (FMCG companies) have globally approved the products.

- New product launches to accelerate growth. SCIL has focused on normalisation of business in H1FY21, and other activities were under freeze. Yellow pigments modification exercise has started in Oct '20, and it expects relaunch by Dec'20. SCIL has guided for one more HPP product in Mar'21, and another in Sep'21 which were earlier planned in FY21. China's change in export rebate to 13% (from nil) in Mar'20 is a headwind for low value pigments. HPP is not materially impacted as these products are mostly sold by BASF / Clariant. Further, SCIL expects cost leadership in many products with completion of backward integration. It continues to see preference to India-based manufacture as buyers are looking to diversify from China.

- Gross margin was stable. Gross margin improved 110bps YoY (20bps QoQ) to 44.2% on better product mix and stable raw material prices. Gross profit rose 3.5% YoY to Rs1.9bn. EBITDA rose 2.1% YoY to Rs677mn. PBT was down 9.6% YoY to Rs425mn on higher depreciation and finance cost on commissioning of new facilities. The company still sources 30-35% of its raw materials from China, which will reduce on backward integration. Positive impact of this on margins will be visible from H2FY22E.

- Capex of Rs6bn will be executed over FY20-22. The company has board approval for capex of Rs5.85bn of which Rs2.25bn has been completed in FY20. It plans to execute capex of Rs2.5bn in FY21E, and Rs1.1bn in H1FY22. A large portion of this capex is towards growth (additional capacity for the existing products and new plant for new products), and some capex for backward integration. The company expects asset turnover of 3x on growth capex. It expects to accelerate investment on backward integration, post board approval, in FY22.

Shares of SUDARSHAN CHEMICAL INDUSTRIES LTD. was last trading in BSE at Rs.470.5 as compared to the previous close of Rs. 487.95. The total number of shares traded during the day was 36682 in over 2376 trades.

The stock hit an intraday high of Rs. 484.65 and intraday low of 467.6. The net turnover during the day was Rs. 17299979.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Views of HDFC Securities and Acuité Ratings & Research on Q2FY21 GDP Numbers

Rollover Report for November 2020 - December 2020: Angel Broking

Initiating Coverage on Godrej Properties - The housing factory - HDFC Securities

Burger King IPO - Angel Broking

Rollover Analysis - Record foreign inflows pushes Nifty to 13k - YES Securities

Ceramic tiles industry - Market share gains sustain for top branded players - ICICI Securities

Gas sector - CGD: Competition to hit margins, volumes and lead to derating - ICICI Securities

Cement - Prices resilient in Q3; consensus upgrades to continue - ICICI Securities

Specialty chemicals - Price trend in Sep-20 - ICICI Securities

Timken India - Q2FY21 Company Update - ICICI Direct

Upgrade in target price of IDFC First Bank - Angel Broking

Laurus Labs stake acquisition in Richore Lifesciences - Angel Broking

Shares of Lakshmi Vilas Bank (LVB) suspended from trading - Angel Broking

Initiating Coverage on Sundram Fasteners - Fastening growth - HDFC Securities

Astral Poly Technik - Scalability to further improve with storage tanks foray - ICICI Securities

Vardhman Special Steel - Q2FY21 Company Update - ICICI Direct

Initiating Coverage - Advanced Enzyme Technologies - ICICI Direct

L&T - Secures Large Contract - Nov 25, 2020 - Angel Broking

Alembic Pharmaceuticals - Tentative Approval for JV - Angel Broking

Drug launch by Lupin - Tacrolimus Capsules - Angel Broking

Gujarat Gas - Nov 25, 2020 - Angel Broking

Metropolis Healthcare - Nov 25, 2020 - Angel Broking

NTPC - Showcase of strength & competitiveness - ICICI Securities

Telecom - Market Share TRACKER - Bharti is narrowing the gap on incremental market share vs RJio - ICICI Securities

Cochin Shipyard - Q2FY21 Result Update - ICICI Direct

Engineers India - Q2FY21 Result Update - ICICI Direct

Rupee - Nov 24, 2020 - Reliance Securities

FMCG Sector Update - Recovery unlocked; lower growth divergence - HDFC Securities

Engineers India - Consultancy segment outperformance - ICICI Securities

Engineers India - Q2 FY21 Result Update - YES SECURITIES

Motherson Sumi Systems - Company Update - Virtual Investor Conference - ICICI Direct

Mutual Fund Review - November, 2020 - ICICI Direct

Sadbhav Engineering - Q2FY21 Company Update - ICICI Direct

IRB Infrastructure - Q2FY21 Company Update - ICICI Direct

Vodafone Idea fund raising - Angel Broking

Rupee - Nov 23, 2020 - Reliance Securities

Crude Oil - Nov 23, 2020 - Reliance Securities

Q2FY21 Bank Result Quick Review - Angel Broking

Banks & NBFC's Sector Update Report - Yet another watershed moment? - HDFC Securities

Galaxy Surfactants - EBITDA/kg has an upside risk - ICICI Securities

Diagnostics - COVID-19 tests continue to trend higher - ICICI Securities

Banking & Financial Services - Sector Update - Nov 22, 2020 - ICICI Direct

Dalmia Bharat Sugar - Q2FY21 Company Update - ICICI Direct

Balkrishna Industries - Industry export growth momentum continues - ICICI Securities

Covid Recovery Pulse - Festive positivity continues in auto retails, E-way bill generation improves... - ICICI Direct

Quant Pick - Exide Industries - ICICI Direct

Shankara Building Products - Q2FY21 Company Update - ICICI Direct

Triveni Engineering - Q2FY21 Company Update - ICICI Direct

Initiating Coverage on Sudarshan Chemical - Leaping into the league of giants - HDFC Securities

Earnings Wrap Q2FY21: Earnings outperform, post Covid recovery picks up steam - ICICI Direct



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019